Publications by authors named "Aristotle Giagounidis"
Purpose: Patients with myelodysplastic syndromes (MDS) often require treatment with growth factors (GFs) or non-GF therapies. One non-GF drug, lenalidomide, is particularly effective at achieving transfusion independence (TI) in patients with lower-risk MDS with the del(5q) cytogenetic abnormality. However, approximately half of del(5q) patients and one quarter of non-del(5q) patients treated with lenalidomide experience significant cytopenias.
View Article and Find Full Text PDFLow-risk myelodysplastic syndrome (MDS) with normal cytogenetics accounts for approximately 50% of MDS patients. There are no pathognomonic markers in these cases and the diagnosis rests on cytomorphologic abnormalities in bone marrow and/or peripheral blood. Affymetrix high-resolution single-nucleotide polymorphism (SNP) genotyping microarrays allow detection of cytogenetically cryptic genomic aberrations.
View Article and Find Full Text PDFArticle Synopsis
- The study focused on the effects of lenalidomide on severe anemia in patients with myelodysplastic syndrome and a chromosome 5q31 deletion.
- Lenalidomide treatment led to a significant decrease in transfusion needs for many patients, with 76% experiencing reduced requirements and 67% becoming transfusion-independent.
- Most patients responded quickly, and the treatment showed sustained benefits, including improvements in cytogenetic abnormalities, although some faced moderate-to-severe side effects requiring dose adjustments.